Cancer Res Treat.  2006 Jun;38(3):133-138.

Patterns of Failure after Postoperative Radiation Therapy for Endometrial Carcinoma

• Kim S
• Wu HG
• Lee HP
• Kang SB
• Song YS
• Park NH
• Ha SW

Abstract

PURPOSE: We tried to investigate the outcome and patterns of failure of endometrial cancer patients who were treated with surgery and postoperative radiation therapy (RT).
MATERIALS AND METHODS
Eighty-three patients with endometrial cancer who received postoperative RT between May 1979 and August 2000 were included in this retrospective study. Forty-one patients received total abdominal hysterectomy, 41 patients received Wertheim's operation and 1 underwent vaginal hysterectomy. Pelvic lymph node dissection or pelvic lymph node sampling was done in 56 patients and peritoneal cytology was done in 35. All the patients were staged according to 1988 FIGO (International Federation of Gynecology and Obstetrics) staging system; 2 were stage IA, 23 were stage IB, 20 were stage IC, 4 were stage IIA, 5 were stage IIB, 9 were stage IIIA, 2 were stage IIIB and 18 were stage IIIC. The histologic diagnoses were adenocarcinoma in seventy-four patients (89%). The histologic grades were Grade 1, 2 and 3 in 21 (25%), 43 (52%) and 10 (12%) patients, respectively. All the patients received external beam RT (EBRT) with a median dose of 5,040 cGy (range: 4,500~5,075 cGy) to the whole pelvis. Five patients with pathologically confirmed paraaortic lymph node metastasis received 4500 cGy to the paraaortic lymph nodes. Fifteen patients received low-dose intracavitary brachytherapy after their EBRT. A total dose of 7,500~9,540 cGy (median dose: 8511) was prescribed to the vaginal surface.
RESULTS
Overall, 11 patients (13%) experienced disease relapse: 4 with initial stage I or II disease and 7 with initial stage III disease. Among the 54 stage I or II patients, 1 (2%) relapsed in the pelvis only, 2 (4%) relapsed in the vagina and distant organs, and 1 (2%) relapsed in the paraaortic lymph nodes (PANs). Among the 29 stage III patients, 1 (3%) relapsed in the vagina. The most common sites of failure for the stage III patients were the peritoneum (3 patients, 10%), PANs (2 patients, 7%), and lung (2 patients, 7%). With a median follow-up period of 86 months, the overall survival (OS) and disease-free survival (DFS) rates at 5 years were 87% for both. The five-year DFS rate was 93%, 100% and 74% for the stage I, II and III patients, respectively. Three patients experienced severe radiation-related late complications: RTOG (Radiation Therapy Oncology Group) grade 3 radiation cystitis was seen in one patient, and grade 3 bowel obstruction was seen in two patients.
CONCLUSIONS
Postoperative RT was useful for controlling pelvic disease. The major patterns of failure for stage III patients were peritoneal seeding and distant metastasis. Selective use of whole abdominal radiotherapy or adjuvant chemotherapy may improve the therapeutic outcome of these patients.

Keyword

Endometrial neoplasms; Postoperative radiation therapy; Patterns of failure

MeSH Terms

Adenocarcinoma
Brachytherapy
Chemotherapy, Adjuvant
Cystitis
Diagnosis
Disease-Free Survival
Endometrial Neoplasms*
Female
Follow-Up Studies
Gynecology
Humans
Hysterectomy
Hysterectomy, Vaginal
Lung
Lymph Node Excision
Lymph Nodes
Neoplasm Metastasis
Pelvis
Peritoneum
Radiotherapy
Recurrence
Retrospective Studies
Vagina

Figure

• 

  Fig. 1 Overall survival curves using the Kaplan-Meier method.

• 

  Fig. 2 Disease-free survival curves using the Kaplan-Meier method.

Reference

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55:10–30. PMID: 15661684.

2. Lee SE, Kim JW, Par NH, Song YS, Kang SB, Lee HP. Contemporary trends of endometrial cancer in Korean women. Korean J Gynecol Oncol. 2005; 16:215–220.

3. International Federation of Gynecology and Obstetrics. Corpus cancer staging. Int J Gynecol Obstet. 1989; 28:190.

4. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53:457–481.

5. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50:163–170. PMID: 5910392.

6. Cox DR. Regression models and life tables. J R Stat Soc. 1972; 34:187–220.

7. Herrmann T, Knorr A, Dorner K. The RTOG/EORTC classification criteria for early and late radiation reactions. Radiobiol Radiother (Berl). 1987; 28:519–528. PMID: 3685293.

8. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92:744–751. PMID: 14984936.

9. Scholten AN, van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, et al. Postoperative radiotherapy for stage I endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005; 63:834–838. PMID: 15927414.

10. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980; 56:419–427. PMID: 6999399.

11. Carey MS, O'Connell GJ, Johanson CR, Goodyear MD, Murphy KJ, Daya DM, et al. Good outcome associated with standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol. 1995; 57:138–144. PMID: 7729725.

12. Grigsby PW, Perez CA, Kuten A, Simpson JR, Garcia DM, Camel HM, et al. Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system. Int J Radiat Oncol Biol Phys. 1992; 22:905–911. PMID: 1555983.

13. Bliss P, Cowie VJ. Endometrial carcinoma: does the addition of intracavitary vault caesium to external beam therapy postoperatively result in improved control or increased morbidity? Clin Oncol (R Coll Radiol). 1992; 4:373–376. PMID: 1463690.

14. Greven KM, D'Agostino RB Jr, Lanciano RM, Corn BW. Is there a role for a brachytherapy vaginal cuff boost in the adjuvant management of patients with uterine-confined endometrial cancer? Int J Radiat Oncol Biol Phys. 1998; 42:101–104. PMID: 9747826.

15. Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley HD, Malfetano JH, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2005; 97:755–763. PMID: 15913742.

16. Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep. 1979; 63:21–27. PMID: 369691.

17. Thigpen JT, Blessing JA, Homesley H, Creasman WT, Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 1989; 33:68–70. PMID: 2703169.

18. Long HJ, Pfeifle DM, Wieand HS, Krook JE, Edmonson JH, Buckner JC. Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Inst. 1988; 80:276–278. PMID: 3280811.

19. Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996; 62:278–281. PMID: 8751561.

20. Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Preliminary analysis of RTOG 9708: adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys. 2004; 59:168–173. PMID: 15093913.

21. Mundt AJ, Waggoner S, Yamada D, Rotmensch J, Connell PP. Age as a prognostic factor for recurrence in patients with endometrial carcinoma. Gynecol Oncol. 2000; 79:79–85. PMID: 11006036.

22. Mariani A, Webb MJ, Keeney GL, Calori G, Podratz KC. Hematogenous dissemination in corpus cancer. Gynecol Oncol. 2001; 80:233–238. PMID: 11161865.

23. Mariani A, Webb MJ, Keeney GL, Lesnik TG, Podratz KC. Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol. 2002; 87:274–280. PMID: 12468325.

24. Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol. 2002; 84:437–442. PMID: 11855884.

25. Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Endometrial cancer: predictors of peritoneal failure. Gynecol Oncol. 2003; 89:236–242. PMID: 12713986.